Preparing for Regulatory Inspection in Cell and Gene Therapy Manufacturing

Regulatory inspections represent a critical validation of manufacturing quality systems in cell and gene therapy. These inspections assess not only whether procedures exist, but whether they are effectively implemented and consistently followed. For advanced therapy manufacturers, inspection readiness reflects the strength, maturity, and reliability of the entire Quality Assurance framework.

At C3i, inspection readiness begins well before an inspection is scheduled.

• Risk assessments and gap analyses provide a structured evaluation of processes, facilities, and documentation, allowing potential vulnerabilities to be identified and addressed proactively. This ongoing process ensures that compliance is embedded within daily operations rather than treated as a short-term preparation exercise. Preparing clear documentation and structured explanations for identified gaps allows teams to demonstrate awareness, control, and a defined plan for resolution during inspection.
• Documentation forms the backbone of inspection readiness. Complete, accurate, and traceable records demonstrate that manufacturing activities are performed according to established procedures and that deviations are appropriately investigated and resolved. Electronic systems compliant with regulatory requirements provide secure audit trails and maintain the integrity of manufacturing and quality data. These records allow organizations to demonstrate control over their processes with confidence.
• Personnel preparation is equally essential. Subject matter experts across Quality Assurance, Quality Control, and Manufacturing must be able to clearly explain their responsibilities and processes. Training ensures that employees understand regulatory expectations and can confidently support inspections. This shared understanding reinforces the integration of quality principles across all functions.
• Facility readiness also plays a key role. Clean, organized workspaces reflect disciplined operations and reinforce confidence in overall process control. Regular internal walkthroughs help identify and resolve potential issues, ensuring that facilities consistently reflect the standards defined within the quality system.
• Effective inspection management relies on coordination and preparation. Dedicated inspection support teams facilitate document retrieval, review, and communication, ensuring that inspectors receive accurate and complete information. Coordinated inspection teams, including personnel supporting both inspector interactions and document preparation, help ensure efficient communication and accurate responses throughout the inspection process. This structured approach allows organizations to maintain control while demonstrating transparency and professionalism.

Inspection readiness ultimately reflects the strength of an organization’s quality culture.

By maintaining robust systems, well-trained personnel, and controlled manufacturing processes, C3i ensures that its operations consistently meet regulatory expectations. This sustained state of readiness supports both compliance and the reliable delivery of advanced therapies to patients.

This article is drawn from material presented during the webinar Navigating Regulatory Expectations for Quality Assurance in Cell and Gene Therapy Manufacturing, presented on February 19th 2026, by C3i’s expert Richard Vaillancourt, PhD (Quality Assurance Director).